SAN ANTONIO--(BUSINESS WIRE)--CeloNova BioSciences, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indication for their innovative Oncozene® and Embozene® microsphere products to now include the embolization of Hepatoma. Hepatoma, also known as Hepatocellular Carcinoma (HCC), is the sixth most common cancer in the world, the third most common cause of cancer-related death, and the leading cause of death in patients with cirrhosis in the United States and Europe1. Oncozene® and Embozene® microspheres are precisely calibrated embolics to treat Hepatomas by stopping the blood flow.
Hey, check out all the research scientist jobs. Post your resume today!
